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Abstract
Ventricular arrhythmias (VAs) arising from the right ventricular outflow tract (RVOT) are a common and heterogeneous entity. Idiopathic right 
ventricular arrhythmias (IdioVAs) are generally benign, with excellent ablation outcomes and long-term arrhythmia-free survival, and must be 
distinguished from other conditions associated with VAs arising from the right ventricle: the differential diagnosis with arrhythmogenic right 
ventricular cardiomyopathy/dysplasia (ARVC/D) is therefore crucial because VAs are one of the most important causes of sudden cardiac 
death (SCD) in young individuals even with early stage of the disease. Radiofrequency catheter ablation (RFCA) is a current option for the 
treatment of VAs but important differences must be considered in terms of indication, purposes and procedural strategies in the treatment 
of the two conditions. In this review, we comprehensively discuss clinical and electrophysiological features, diagnostic and therapeutic 
techniques in a compared analysis of these two entities.
Introduction
The right ventricular outflow tract (RVOT) is the most common 
origin of non-ischemic ventricular arrhythmias (VAs). RVOT VAs 
- including premature ventricular contractions (PVCs) and non-sus-
tained or sustained ventricular tachycardia (VT) - are the expression 
of two different entities, both in terms of natural history and in terms 
of therapeutic management: idiopathic right ventricular arrhythmias 
(IdioVAs) and arrhythmogenic right ventricular cardiomyopathy/
dysplasia (ARVC/D).1,2
IdioVAs is a benign condition that occurs in young adults without 
structural heart disease, traditionally considered a primary electrical 
disease, responsive to medical and ablative therapy.3,4 ARVC/D is a 
autosomal dominant genetically determined heart muscle disorder 
characterized by pathological fibro-fatty replacement of the right 
ventricular (RV) myocardium, that leads to VAs, RV dysfunction 
and sudden cardiac death (SCD).5-7 In the early stage of the disease, 
structural changes may be absent or subtle, progressively affecting 
localized areas of the RV, typically the inflow tract, outflow tract, 
or apex of the RV, the so-called “triangle of dysplasia”.8 However, 
the subsequent involvement of other regions of the RV is common.9 
Whilst in the past the involvement of the left ventricle (LV) was 
considered an expression of the final stage of the disease, known as 
“biventricular failure phase”, it is currently recognized that ARVC/D 
can present with isolated or predominant involvement of LV since 
the early stages.10 Clinical and genetic characterization of families 
demonstrated 3 different patterns of ARVC/D: classic pattern with 
predominant RV disease; left dominant pattern, with early and 
prominent LV disease; bi-ventricular pattern, with synchronous 
involvement of both ventricles.11 The diagnosis of ARVC/D relies on 
the demonstration of structural, functional, and electrophysiological 
abnormalities, as defined by the 2010 modified Task Force criteria 
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different procedural endpoints should be defined and different 
ablation strategies are required.13-15
Electrophysiological Properties Of The Embryonic Outflow 
Tract Related To Ventricular Arrhythmias In Adults 
Anatomically, four portions of RVOT are described: rightward, also 
adapted to improve diagnostic sensitivity.12
Radiofrequency catheter ablation (RFCA) is a highly effective 
treatment for symptomatic patients with IdioVAs, whilst the 
role of ablation in ARVC/D is not definitively curative. As such, 
differentiating between the two conditions is essential because 
Table 1: Revised Task Force (TF) criteria of 2010.12
Global or regional dysfunction and 
structural alterations
Major Criteria
   - 2D echo Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following (end diastole):
PLAX RVOT ≥32 mm (corrected [PLAX/BSA] ≥19 mm/m2)
PSAX RVOT ≥36 mm (corrected [PSAX/BSA] ≥21 mm/m2)
or fractional area change ≤33%
   - MRI Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following:
Ratio of RVEDV to BSA ≥110 mL/m2 (male) or ≥100 mL/m2 (female)
or RV ejection fraction ≤40%
   - RV angiography Regional RV akinesia, dyskinesia, or aneurysm
Minor Criteria
   - 2D echo Regional RV akinesia or dyskinesia and 1 of the following (end diastole):
PLAX RVOT ≥29 to <32 mm (corrected [PLAX/BSA] ≥16 to <19 mm/m2)
PSAX RVOT ≥32 to <36 mm (corrected [PSAX/BSA] ≥18 to <21 mm/m2)
or fractional area change >33 to ≤40%
   - MRI Regional RV akinesia or dyskinesia or dyssynchronous RV contraction and 1 of the following:
Ratio of RVEDV to BSA ≥100 to <110 mL/m2 (male) or ≥90 to <100 mL/m2 (female)
or RV ejection fraction > 40 to ≤45%
Tissue characterization of wall
Major Criteria Residual myocytes <60% by morphometric analysis (or <50% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, 
with or without fatty replacement of tissue on EMB
Minor Criteria Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 
sample, with or without fatty replacement of tissue on EMB
Repolarization abnormalities
Major Criteria Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals >14 years of age (in the absence of complete RBBB QRS ≥120 ms)
Minor Criteria Inverted T waves in leads V1 and V2 in individuals >14 years of age (in the absence of complete RBBB) or in V4, V5, or V6
Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of age in the presence of complete RBBB
Depolarization/conduction abnormalities
Major Criteria Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)
Minor Criteria Late potentials by SAECG in ≥1 of 3 parameters in the absence of a QRS duration of ≥110 ms on the standard ECG
Filtered QRS duration (fQRS) ≥114 ms
Duration of terminal QRS <40 μV (low-amplitude signal duration) ≥38 ms
Root-mean-square voltage of terminal 40 ms ≤20 μV
Terminal activation duration of QRS ≥55 ms measured from the nadir of the S wave to the end of the QRS, including R’, in V1, V2, or V3, in the absence 
of complete RBBB
Arrhythmias
Major Criteria Non-sustained or sustained VT of LBBB morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL
Minor Criteria Non-sustained or sustained VT of RV outflow configuration, LBBB morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in 
lead aVL) or of unknown axis)
>500 ventricular extrasystoles per 24 hours (Holter)
Family History
Major Criteria ARVC/D confirmed in a first-degree relative who meets current TF criteria
ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative
Identification of a pathogenic mutation categorized as associated or probably associated with ARVC/D in the patient under evaluation
Minor Criteria History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current TF criteria
Premature SCD (<35 years of age) due to suspected ARVC/D in a first-degree relative
ARVC/D confirmed pathologically or by current TF criteria in a second-degree relative
RV = right ventricle, PLAX = parasternal long-axis, RVOT = right ventricular outflow tract, BSA = body surface area, PSAX = parasternal short axis, RVEDV = right ventricular end-diastolic volume, EMB = 
endomyocardial biopsy, RBBB = right bundle-branch block, SAECG = signal-averaged ECG, LBBB = left bundle-branch block, SCD = sudden cardiac death
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(88%), earliest QRS onset in V1 (90%), late (V5; 90%) and very late 
(V6; 100%) precordial transition were all highly specific criteria.31
For clinical purposes, ECG characteristics of different sites of 
RVOT and the left ventricular outflow tract (LVOT) VAs are given 
in Table 2.32,33 
In the Revised Task Force criteria, Signal Averaged 
Electrocardiography (SAECG) is a minor criterion of ARVC/D.12 
However, O’Donnell and coworkers found that late potentials (LPs) on 
the SAECG were not present in any patient with RVOT tachycardia 
but were present in 78% of the patients with ARVC/D.34 Moreover, 
in a recent non-invasive ECG study, the SAECG parameters and the 
frequency components recorded from the wavelet-transformed ECG 
were compared between three different groups: IdioVAs, ARVC/D 
and Brugada syndrome. Focusing on the first two entities, LPs were 
positive in all of ARVC/D patients whilst were negative in all of 
IdioVAs patients and high-frequency components (80-150 Hz) were 
developed in ARVC/D but not in IdioVAs.35
Electrophysiological Differences Between IdioVAs And 
Ventricular Arrhythmias In ARVC/D 
Taking into account the different underlying substrate of the two 
entities, electrophysiological findings help to differentiate IdioVAs 
from VAs in the setting of ARVC/D.
Different groups compared electrophysiological findings in 
patients with IdioVAs and ARVC/D reporting similar results.30,34 
IdioVAs are due to cyclic AMP mediated triggered activity. Thus, 
it is a focal form of tachycardia, frequently presenting in form of 
non-sustained arrhythmias, sensitive to catecholamine infusion (i.e. 
epinephrine, phenylephrine or isoproterenol) and burst stimulation; 
for the same reason IdioVAs are monomorphic with the common 
inferior axis – LBBB morphology and present a presystolic high 
amplitude local electrogram.36,37
VAs in context of ARVC/D are the expression of slow conduction 
areas within the diseased myocardium that allow continuous electrical 
activity, fragmented diastolic potentials (figure 2) in an expanded 
area, creating a circuit pathway. For this reason, programmed 
ventricular stimulation is more effective to induce VT in ARVC/D 
patients compared with IdioVAs.38,39 Moreover, the evidence of 
different reentry pathways justifies the inducibility of multiple VT 
morphologies that may be common in ARVC/D patients. 
Imaging - Cardiac Magnetic Resonance 
Cardiac magnetic resonance (CMR) imaging is increasingly used 
as a standard technique for imaging of RV structure and function. 
Indeed, CMR is the most reliable modality available for the 
quantification of ventricular size and volume and for the detection of 
RV morphological abnormalities due to its capacity to perform tissue 
characterization.
called free wall, anterior, leftward, and posterior. The myocardium is 
relatively thin in the rightward, anterior, and leftward portions of the 
RVOT, whilst the posterior infundibular part is the thickest16 (figure 
1). In the developing embryonic heart, the presence of “transitional 
zones”, with slow conducting properties, seems to be related to the 
presumptive cardiac conduction system.17 One of these transitional 
zones is found in the myocardial outflow tract. Several markers 
related to the developing cardiac conduction system have been 
described in these zones,18 including the Hyperpolarization-activated 
cyclic nucleotide-gated channel 4 (HCN4), that is responsible for the 
current in the sino-atrial node (If ).19 The expression of HCN4 among 
other markers (such as CCS-lacZ and MinK-lacZ20,21), in RVOT of 
the developing heart may explain the occurrence of arrhythmias in the 
adult heart. Re-expression of an embryonic phenotype, or embryonic 
remnants of tissue may provide the arrhythmogenic potential of this 
area.22
Clinical Presentation And ECG Of Ventricular Arrhythmias 
In Patients With IdioVAs And ARVC/D 
Clinical presentation of IdioVAs typically includes palpitations, 
dizziness, related to frequent PVCs or non-sustained VT. Less 
frequently, physical exercise or emotional stress can lead to 
sustained VT that may be occasionally the cause for syncope. On 
the other hand, clinical presentation of ARVC/D may be variable: 
palpitations, but also syncope, cardiac arrest or SCD have been 
reported. Traditionally, 3 different phases have been distinguished. 
In the early “concealed phase”, patients are commonly asymptomatic, 
with minor VAs and subtle RV structural changes. However, risk of 
SCD is reported particularly during exercise.5 In the second phase, 
“overt electrical phase”, patients present symptomatic VAs and 
morphological RV abnormalities detected by imaging. Finally, the 
third phase is the “end-stage-disease”, often indistinguishable from 
dilated cardiomyopathy.23
Several ECG markers related to ARVC/D have been described.24-29 
According to the Revised Task Force criteria, summarized in Table 
1, evidence of negative precordial T-wave in V1-V3 or beyond and 
epsilon wave in V1-V3 on sinus rhythm are major criteria.12 
Regarding presentation with Vas, the typical inferior axis / left 
bundle branch block (LBBB) pattern is common in more than 
90% of IdioVAs patients. Differently, ARVC/D patients present 
with inferior axis as well as intermediate axis or superior axis VAs.30 
Recently, Hoffmayer et al. compared ARVC/D and IdioVAs patients 
in a population presenting with the same inferior axis / LBBB ECG 
morphology, finding several distinguishing criteria between the two 
conditions. With regard to the diagnosis of ARVD/C, QRS duration 
≥ 120 ms in lead I was highly sensitive (88%), whereas a “notching” 
on QRS upstroke (88%), multiple QRS notching in different leads 
Table 2:
Outflow tract VAs origin based on QRS pattern. ECG differentiation of a RVOT from a LVOT origin VAs is based on the R/S precordial 
transition.32-33
Right ventricle BBB Axis Precordial transition V1 V6 other
RVOT septal LBBB Inferior ≤ V3 rS R (-) polarity of lead I in anterior and leftward location; (+) polarity in posterior and rightward 
location; multiphasic polarity in midway location.
RVOT free-wall LBBB Inferior ≥ V3 rS R (-) polarity of lead I in anterior and leftward location; (+) polarity in posterior and rightward 
location; multiphasic polarity in midway location. Notching in lead II, III and aVF.
LCC LBBB Inferior ≤ V2 QS/QR R
RCC LBBB Inferior ≥ V3 Multiphasic “M” or “W” R
AMC “RBBB” Inferior ≤ V3 qR R
LBBB = left bundle branch block; LCC = left coronary cusp; RCC = right coronary cusp; AMC = aorto-mitral continuity.
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ARVC/D; DE predominantly involved the RV free wall but also 
affected the RV side of the ventricular septum and, in most of the 
patients, it was associated with regional contraction abnormality.48 
A significant inter-observer variability in the interpretation of 
qualitative findings and segmental contraction analysis of the RV 
free wall was reported: CMR was implicated in the overdiagnosis of 
ARVC/D based on the low specificity of qualitative findings, such 
as increased intramyocardial fat and wall thinning.49 A CMR study 
demonstrated a 93.1% prevalence of RV wall motion abnormalities 
in healthy subjects, including areas of apparent dyskinesia (75.9%) 
and bulging (27.6%).50 These data indicate that conventional 
CMR may lead to misdiagnosis of ARVC/D by showing equivocal 
morphofunctional RV abnormalities. Noteworthily, even if CMR is 
considered an important test for ARVC/D diagnosis may not detect 
the initial phases of the disease.
The Adjunctive  Role Of Three-Dimensional 
Electroanatomical Voltage Mapping
Three-dimensional electroanatomical voltage mapping 
(3D-EAVM) using CARTO system (Biosense-Webster, Diamond 
Bar, CA, USA) is able to unmask subtle structural heart disease 
in patients with VAs and an apparently normal heart, despite a 
thorough noninvasive evaluation, including CMR.51 Specifically, 
3D-EAVM accurately identifies and characterizes low-voltage 
regions (“electroanatomical scar”) that, in patients with ARVC/D, 
correspond to areas of myocardial depletion and correlate with 
Although IdioVAs occur in patients with no structural heart 
disease, several groups reported that CMR imaging detected 
structural abnormalities in patients with IdioVAs, which are similar 
to those seen in the early stages of ARVC/D. CMR showed 
subtle areas of diminished wall motion and suggested that mild 
structural abnormalities may be present.40-43 These findings made the 
differentiation of ARVC/D and RVOT tachycardia at the time of 
initial diagnosis more difficult in some patients. In clinical routine 
CMR imaging is of fundamental value in the diagnosis of ARVC/D; 
however, a suspicion of ARVC/D cannot be confirmed or excluded 
based on CMR imaging alone.
On the other hand, it is well established that the typical 
morphological features of ARVC/D are RV dilatation and/or 
dysfunction, wall motion abnormalities, diastolic bulging, wall 
thinning, reduced systolic thickening and trabecular disarray.44 
Moreover, CMR has the unique ability to detect diffuse or segmental 
replacement of myocardium in the RV free wall by fibro-fatty 
tissue.45 Delayed enhancement (DE) CMR is effective in detecting 
the presence, location, and extent of myocardial scarring. DE has 
been described in areas of fibro-fatty myocardial changes in patients 
with ARVC/D.46 Tandri et al.47 first reported an excellent correlation 
between DE and histopathological diagnosis of fibro-fatty infiltration 
in patients with ARVC/D. Moreover, they showed that the presence 
of RV DE was predictive of inducible VT during electrophysiological 
study. Another group reported DE in 88% of patients studied with 
Figure 1:
RVOT can be thought of as a cylinder that wraps around LVOT. RVOT courses anterior to the LVOT, from a rightward inferior to a leftward 
superior direction, such that the pulmonary valve lies to the left and anteriorly to the aortic valve. The pulmonary annulus is cephalad to the 
aortic annulus thus the structure immediately anterior to the aortic valve, specifically the right coronary cusp and part of the left coronary 
cusp, is the posterior muscular infundibular portion of the RVOT.
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in ARVC/D patients.56 These results were however not confirmed 
by the histopathological study.56 Differently, Corrado et al.57 
demonstrated that some patients with RVOT VT in the absence of 
RV dilatation and/or dysfunction showed electroanatomical scar in 
the RVOT corresponding to histopathological features diagnostic of 
early ARVC/D, like fibro-fatty myocardial replacement, conditioning 
malignant arrhythmic course. This was consistent with the current 
perspective on the ARVC/D natural history, and with an early 
“concealed” phase with subtle RV structural changes that can be 
identified by 3D-EAVM with a high degree of sensitivity of 100% 
and specificity of 95%.57 Santangeli et al.58 compared CMR with 
3D-EAVM for scar identification in patients with RV arrhythmias 
and structural heart disease evidenced at EMB, confirming that 
3D-EAVM is more sensitive than DE-CMR, particularly in cases 
of small scars, and should be used as mapping guide for EMB. Their 
conclusion was that 3D-EAVM with EMB should be considered 
when the clinical suspicion is high, because absence of DE does not 
reliably rule out abnormal myocardial substrates.58
Recently, Perazzolo Marra and co-workers confirmed that currently 
available DE-CMR visualizes RV scars unsatisfactorily: based on 
their findings, it seems that DE-CMR and 3D-EAVM should not be 
considered alternative imaging tools in ARVC/D patients, but they 
should be used synergistically to combine their strategic diagnostic 
and prognostic information regarding quantitative evaluation of RV 
function and assessment of arrhythmogenic myocardial substrate.59 
A new technique to predict the presence and extension of epicardial 
involvement in patients with ARVC/D undergoing endocardial 
EAVM was proposed by the Marchlinski’s group. This technique 
shows that, in patients with limited endocardial substrate, endocardial 
unipolar intracardiac electrograms (EGMs) <5.5 mV well correlate 
with electrogram abnormalities detected from the epicardial aspect in 
patients with ARVC/D:61 therefore endocardial unipolar electrogram 
abnormalities may represent the clue of an early “epicardial” disease, 
that requires further investigation (figure 3).  
Radiofrequency Catheter Ablation In IdioVAs And ARVC/D
RFCA of IdioVAs arising from the RVOT is based on two main 
methods of mapping: activation mapping and pace-mapping. In 
addition, both available 3D-EAVM systems, CARTOTM (Biosense-
Webster, Diamond Bar, CA, USA) or NavXTM (St. Jude Medical, 
St. Paul, MN, USA), are widely used to relate the anatomy to the 
mapping data (figure 4, panel A). During activation mapping, the 
earliest intracardiac bipolar electrogram recorded from the mapping 
catheter is compared with the surface QRS onset, with an expected 
advance of 20 to 40 milliseconds (figure 4, panel B-C); a sharp “QS” 
deflection at the unipolar recording should confirm the site of origin 
of the arrhythmia. Of note, unipolar EGMs have been related to a 
high sensitivity for successful ablation sites, but may also be recorded 
at unsuccessful sites up to 11 mm from the site of origin.26,62-64 
Pacemapping has been proposed to confirm the activation mapping 
findings and in particular if PVCs are not frequent or VT is not 
inducible. It should be performed using as little current as needed 
to reliably capture and at the same cycle length of VT or similar, 
and perfect match on a 12-lead ECG with regard to spontaneous 
arrhythmias is mandatory.65-67
Accordingly to the available published data in respect of the 
outcome of RFCA for IdioVAs, acute procedural success was 
reported in 93% of patients, with about 5% of recurrence risk.68 
the histopathological finding of myocardial atrophy and fibro-
fatty replacement confirmed at endomyocardial biopsy (EMB).52-55 
Boulos et al.56 compared electroanatomical findings in patients with 
an ultimate diagnosis of IdioVAs with those in patients who had 
established ARVC/D. They found that mapping results were in 
concordance with previous clinical diagnosis, by showing normal 
voltages in the IdioVAs group and abnormal low-amplitude areas 
Figure 2:
Electroanatomical endocardial 3D mapping shows a large diseased 
area in the antero-septal portion of the RVOT (<0.5 mV), where 
fragmented low-voltage electrograms are detected (Panel A, 
left and right), diagnostic of arrhythmogenic right ventricular 
cardiomyopathy/dysplasia. VT 12-lead ECG (Panel B) and 
intracardiac electrograms (Panel C) are shown: radiofrequency 
delivery at the site of interest, where a diastolic fragmented 
activity is recorded, immediately terminates the VT.
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mostly due to the relatively thin structure of the RVOT.16 
RFCA of VAs in ARVC/D patients is not considered curative and 
thus is not a first-line therapy.13-15 The results of RFCA in the setting 
of ARVC/D-related VAs substantially vary among the several single-
Serious complications were described in approximately 1% of 
patients, primarily related to myocardial perforation. For this reason, 
the integration with the new available technologies, such as contact 
force information, is mandatory to reduce the risk of perforation 
Figure 3:
Electroanatomical bipolar endocardial mapping (left anterior oblique, LAO) and right anterior oblique, RAO) views, Panel A and B) is 
characterized by normal voltage electrograms in the entire right ventricular chamber. Unipolar electrogram analysis shows however in the 
anterior aspect of the ventricle/RVOT a narrow area where abnormal electrograms (red;  <5.5mV) are recorded; this evidence suggests 
epicardial substrate abnormalities as an initial stage of the disease, that are confirmed by direct epicardial bipolar mapping (<1.0mV).
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papers published.13,14,53,55,69-71 These unsatisfactory results achieved 
with RFCA may be related to an inadequate characterization of the 
substrate. Considering the diffuse substrate of ARVC/D and the 
predominant epicardial involvement and taking into account the 
relevant incidence of failure using an endocardial-only approach, 
Garcia et al.60 described the role of a combined endo-epicardial 
substrate-based ablation approach to improve the outcomes in 
ARVC/D patient population. In this study the feasibility of 
endo-epicardial substrate–based approach to improve arrhythmia 
control was demonstrated, underlying importance of targeting 
the epicardium to further optimize long-term clinical outcome.60 
During a mean follow-up of 18±12 months from RFCA, 77% of 
patients have no VT recurrence.60 Bai and coworkers72 interestingly 
suggested that the endo-epicardial approach not only increased 
long-term arrhythmia-free survival but was more likely to result in 
discontinuation of antiarrhythmic drugs. Berruezo et al.73 showed 
that a combined endo-epicardial mapping reveals larger epicardial 
substrate in patients with ARVC/D, confirming the low efficacy of 
the endocardial-only strategy. Moreover, it was demonstrated that 
using the endo-epicardial approach including scar dechannelling 
technique is possible to achieve a high acute success rate with low 
incidence of recurrence during follow-up.73
RFCA results in a significant reduction in the VT burden among 
patients with ARVC/D, regardless of ablation strategy. However, 
despite the better results using the epicardial approach, recurrence 
rates remain considerable as shown by Philips et al.74 In their series of 
87 ARVC/D patients undergoing RFCA, they reported a cumulative 
freedom from VT after epicardial ablation of 64% and 45% at 1 and 
5 years, which was significantly longer than with the endocardial 
approach.74
Conclusion
IdioVAs and ARVC/D, even at the early stage, are fundamentally 
different entities. Nevertheless, clinical presentation is not 
unequivocal, so that, particularly in early stage of ARVC/D, non-
invasive diagnostic tools may direct towards one or the other 
suspected diagnosis. ECG differences in sinus rhythm between 
IdioVAs and early stage ARVC/D may be unremarkable, whilst, 
during VAs different ECG and intracardiac findings have been 
identified to assist in the differential diagnosis. Currently available 
imaging techniques are of fundamental importance to recognize 
RV structural and functional abnormalities and the combined 
information derived from CMR and 3D-EAVM represent the most 
effective tool for the identification of myocardial abnormalities in 
early stages of the disease. The role of RFCA is well established in the 
setting of IdioVAs, whilst more and more evidences support the use of 
a combined endo-epicardial substrate-based approach to effectively 
control the arrhythmic burden in ARVD patients, modifying the 
course of the disease in a prognostic way.
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